The costs for IRB review of research conducted at a single institution by that institution’s IRB have typically been considered an indirect cost covered under an institution’s Facilities and Administration (F&A) rate (except for industry-initiated-and-sponsored studies). However, many institutions who will serve as single IRBs (sIRBs) will charge fees to review other sites. Additionally, fees charged by independent IRBs, such as WCG IRB or Advarra, will not be paid for by the institution. The fees are the responsibility of the lead site and should be included in the grant budget as direct costs. This is a new responsibility.
The lead site will have additional responsibilities for coordinating sIRB review and requirements throughout the life of the study which may require additional staffing resources.
Each IRB determines whether or not it will charge study-specific fees. In general:
Read the list of options for single IRB review for UW PIs for more information about which specific IRBs charge fees.
There is no nationwide standard or federal mandate for how IRB fees are assessed or how much they are. Some IRBs charge for each review action they complete (e.g. initial approval, modifications, continuing review) for each site. Some IRBs charge annual fees for the study based on the number of sites. For others, the fees vary based on institutional or organizational affiliations.
You should obtain fee information from the IRB that is specific to the study you are proposing. This may require asking the IRB office for a study-specific fee estimate. Consult the list of options for single IRB review for UW PIs for how to contact IRBs to obtain information about fees.
NIH is expecting that funding proposals may include fees for sIRB review as direct costs and has provided detailed information at the sIRB FAQ and a specific costs guidance document, including topics such as:
If you have questions, contact:
Other federal funding agencies have not issued guidance on budgeting for IRB fees or additional personnel to support sIRB review.